Survey
Quarterly Survey: TVTX's Filspari (sparsentan) and CALT's Tarpeyo (budesonide) in treating IgAN January 2024
Ticker(s): TVTX, CALTSurvey results include 20 physicians treating patients with IgAN.
How many IgAN patients do you have under your care?
Are you familiar with Filspari (sparsentan) and the data to date? / Are you familiar with Tarpeyo (budesonide) and the data to date?
- Yes
- No
How many of your IgAN patients do you treat with Filspari (sparsentan) today?
How many of your IgAN patients started Filspari (sparsentan) in the last 30 days?
How many of your IgAN patients discontinued Filspari (sparsentan) in the last 30 days?
How many of your IgAN patients do you expect to treat with Filspari (sparsentan) in the last 30 days?
How many of your IgAN patients do you treat with Tarpeyo (budesonide) today?
How many of your IgAN patients do you expect to treat with Tarpeyo (budesonide) in the next 30 days?
How would you rate Filspari (sparsentan) on the following (where 1 is low and 5 is high)? / How would you rate Tarpeyo (budesonide) on the following (where 1 is low and 5 is high)?
- Safety
- Efficacy
- Patient access
In your opinion, how effective is Filspari (sparsentan) in treating IgAN compared to other treatments available?
Please elaborate on your view of Filspari (sparsentan).
What is the typical length of the following treatments?
- Filspari
- Tarpeyo
Have you experienced any difficulties with the Filspari REMS program?
In your opinion of reducing proteinuria, what is a meaningful delta in terms of stabilization?
Assuming Filspari’s conversion from accelerated approval to full approval, do you expect usage to increase? If yes, what % do you expect your usage of Filspari to increase?
On a scale 1-10 (where 1 is low and 10 is high) how excited are you for Filspari (sparsentan) in treating IgAN?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
